The Anti-CD40L Monoclonal Antibody AT-1501 Promotes Islet and Kidney Allograft Survival and Function in Nonhuman Primates

An anti-CD40L-specific monoclonal antibody, AT-1501 (Tegoprubart), was engineered to minimize risk of thromboembolic complications by reducing binding to Fcγ receptors expressed on platelets while preserving binding to CD40L.